TCP
PBYI icon

Tourbillon Capital Partners’s Puma Biotechnology PBYI Stock Holding History

Tourbillon Capital Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-300,000
Closed -$17.7M – 64
2018
Q2 		$17.7M Buy
+300,000
New +$17.4M 0.69% 45

Other funds holding PBYI

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Tourbillon Capital Partners's PBYI Position: Q4 2018 in Review

Tourbillon Capital Partners sold out of Puma Biotechnology (PBYI) in Q4 2018, closing a stake of 285,091 shares — an estimated $13.1M sold.

Tourbillon Capital Partners first reported a position in PBYI in Q1 2014 and held it in 8 quarters. The position peaked at $37.1M in Q2 2018. 141 funds tracked by Wall St. Rank hold PBYI as of Q4 2018.

  • Tourbillon Capital Partners reported no remaining Puma Biotechnology position as of Q4 2018 after selling out during the quarter.
  • Tourbillon Capital Partners sold 285,091 Puma Biotechnology shares in Q4 2018, an estimated $13.1M.
  • Tourbillon Capital Partners first reported a position in Puma Biotechnology in Q1 2014 and held it in 8 quarters.
  • Tourbillon Capital Partners's Puma Biotechnology position peaked at $37.1M in Q2 2018.
  • 141 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2018.

Based on Tourbillon Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.